Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07095517CT.gov Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Adenoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tirzepatide (this asset) | Massachusetts General Hospital | P1 | CC · 43 |
| Umbellatine | Jing-yuan Fang, MD, Ph. D | P2/3 | B |
| Mesalamine | UMC Utrecht | P2 | B |
| Celecoxib | University of Alabama at Birmingham | P2 | B |
| Linaclotide | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC |
| muc1 peptide-poly-iclc vaccine | National Cancer Institute (NCI) | P2 | CCC |
| Aspirin | University of Edinburgh | P2 | CCC |
| amr101 | Massachusetts General Hospital | P1/2 | CCC |
| Sinecatechins | Mayo Clinic | P2 | CCC |
+3 more in the Colorectal Adenoma cohort
Other indications for Tirzepatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 1 Diabetes Mellitus | — | P4 | BBB · 78 |
| Psoriatic Arthritis | — | P4 | BBB · 74 |
| Diastolic Heart Failure | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tirzepatide in Colorectal Adenoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tirzepatide-colorectal-adenoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →